Skip to Content
Merck
  • USP7 promotes proliferation of papillary thyroid carcinoma cells through TBX3-mediated p57KIP2 repression.

USP7 promotes proliferation of papillary thyroid carcinoma cells through TBX3-mediated p57KIP2 repression.

Molecular and cellular endocrinology (2020-09-24)
Peiyi Xie, Hui Wang, Jing Xie, Zhaoxia Huang, Sha Chen, Xiuzhi Cheng, Xinyue Zhang, Fanrong Liu, Yun Li, Da Huang
ABSTRACT

Ubiquitin-specific protease 7 (USP7/HAUSP) is known to regulate multiple cellular phenomena, including cell cycle progression and proliferation, and is involved in binding and stabilizing specific target proteins through deubiquitylation. However, the detailed role of USP7 in papillary thyroid carcinoma (PTC) remains to be investigated. In this study, our results showed that USP7 was upregulated in PTC tissues compared with adjacent nontumour tissues. Consistently, a series of gain/loss functional assays in vivo and in vitro demonstrated the role of USP7 in promoting PTC cell proliferation. Furthermore, we showed that there was a negative correlation between USP7 and the CDK inhibitor p57KIP2 expression in PTC tissues and that USP7 facilitated PTC cell proliferation by inhibiting p57KIP2. Mechanistically, USP7 inhibited p57KIP2 expression by modulating TBX3, directly binding to TBX3, and decreasing its ubiquitination and degradation. Our findings demonstrated that USP7 played a critical oncogenic role in PTC tumorigenesis, suggesting that USP7 might act as a prognostic and therapeutic target for PTC progression.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
MISSION® esiRNA, targeting human TBX3
Sigma-Aldrich
MISSION® esiRNA, targeting human USP7